Contraceptive Antibody ZB-06 Vaginal MPT Film
HC4-N, KB15A
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal Gel
-
Intended Duration:
- Pericoital
- Development Stage: Phase I
- Developer(s)/researcher(s): Boston University, ZabBio, KBio, Magee-Womens Research Institute, Eastern Virginia Medical School
Details
- API: Human Contraceptive Antibody
- Target: CD52g
-
Mechanism of Action:
- Inhibition of Sperm Capacitation
- Inhibition of Sperm Motility
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Undetermined
- Promising Attributes: HCA-based film may provide protection against transmission of HIV and HSV, in addition to a contraceptive effect. The film would be user controlled and used on-demand.
Product Status
Active/Recent Clinical Research
History
Boston University and ZabBio have received NIH funding for development of monoclonal antibody-based contraceptive and MPT products since 2018, leading a coalition of partners (including EVMS/Old Dominion University, UT Health, and Magee-Women's Research Institute + manufacturing partner KBio) through lead compound refinement, film design, product manufacturing, and Phase 1 clinical evaluation. As of 2025, Boston University and ZabBio are focused on advancing their product ZB-06 (also referred to as KB15A) through additional clinical trials, a process which requires scaling up production and IND enabling studies. A Phase 1 study evaluating safety and PK is scheduled to initate in 2026, with a Phase 2b planned to follow. In parallel, Magee-Women's is leading product development intended to produce a longer release from the film.